You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
A2A receptor blockade for sepsis
SBC: Purine Pharmaceuticals Inc. Topic: NIAIDSUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
AC5 Inhibitor for Obesity
SBC: VASADE BIOSCIENCES, INC. Topic: NIDDKDESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes
SBC: BIONIKS Topic: NIAMSDESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A cost-effective bioreactor to advance functional tissue engineering of cartilage
SBC: Apex Biomedical Company, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Additive Manufactured PEKK Implants for Small Bone Arthroplasty
SBC: Oxford Performance Materials, Inc. Topic: NIAMSABSTRACT This Phase I STTR is designed to evaluate the feasibility of using the OsteoFabtechnology platform for joint arthroplastyArthroFabdevicesspecifically targeting replacement of the small carpal bones in the wrist and hemiarthroplastyOsteoFabtechnology is the combination of Oxford Performance Materialsandaposproprietary formulation of polyetherketoneketoneOXPEKKpolymerand additive manufactur ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma
SBC: Avenzoar Pharmaceuticals, Inc. Topic: 102ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Advanced Cannula Development for Coronary Sinus Access
SBC: STRATEGIC PACING SYSTEMS LLC Topic: NHLBIDESCRIPTION provided by applicant This Phase STTR will develop novel techniques for coronary sinus access The coronary sinus provides unique anatomic and physiologic proximity to all four cardiac chambers and the coronary circulation For example the coronary sinus is used for left ventricular lead insertion for biventricular pacing or cardiac resynchronization Mor than such implan ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Advanced Polymer-Based Micro-sensor for Radiation Detection and Measurement
SBC: SEACOAST SCIENCE, INC. Topic: NIEHSProject Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Advancing clemizole for hepatitis C: towards a pre-IND package
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health